Russian Heart Failure Journal 2008year Role of a clinical pharmacologist in the treatment of chronic heart failure


To access this material please log in or register

Register Authorize
2008/

Role of a clinical pharmacologist in the treatment of chronic heart failure

Sinitsina I.I., Boeva O. A., Orlov V. A.

Keywords:

DOI:

Urgency. The gap between evidence-based potentialities of drug therapy in patients with CHF and actual quality of their medical care in the conditions of a real healthcare system is obvious. Ongoing efforts are focused on new approaches to reducing this gap. One of such approaches is the active participation of clinical pharmacologists in the process of treatment; efficacy of this approach is currently intensively studied. Aim. To study the role of a clinical pharmacologist in current management of patients with III-IV NYHA FC CHF. Materials and methods. Study enrolled 100 patients with pronounced III-IV FC CHF of different etiology. Patients were educated on pharmacological methods of treatment during hospitalization; therapeutic regimen was determined before discharge; safety and efficacy were followed up during the outpatient period. Patients were evaluated by common clinical methods including physical examination, ECG, echoCG and X-ray. The following methods were used: subjective evaluation by the physician; the Duke Activity Status Index (DASI); 6 min walking test; and quality of life (QOL). Results. It was shown that the proportion of patients adherent to physicians’ recommendations on the non-drug treatment providing control of CHF symptoms at home considerably increased due to the education in the intervention group. At the same time the proportion of patients adherent to the non-drug treatment remained low after 6 months, although the number of such patients increased in the control group. Economic evaluation of the outcome in the group of multitype intervention performed in our study showed a high cost effectiveness of the intervention. Therefore participation of a clinical pharmacologist in the management of patients with pronounced III-IV FC CHF provides a considerable improvement in the quality of drug therapy. The increased quality of drug treatment in patients with pronounced CHF was associated with significantly reduced need for repeated admission, improved functional condition of patients, and a tendency to improved quality of life.
    1.    U. S. Department of Health and Human Services (DHHS). (1994). Heart failure: Management of patients with left ventricular systolic dysfunction (AHCPR Publication No. 94–0613). Rockville, MD: Author.
    2.    Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316 (23):1429–355.
    3.    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325 (5):293–302.
    4.    Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327 (10):669–677.
    5.    Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342 (8875):821–828.
    6.    Packer M, Bristow MR Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334 (21):1349–1355.
    7.    CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet. 1999;353 (9146):9–13.
    8.    MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
    9.    Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
    10.    Mair FS, Carowley TS, Bundred PK. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract. 1996;46 (403):77–79.
    11.    Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 1994;71 (6):584–587.
    12.    Stafford RS, Saglam D Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med. 1997;157 (21):2460–2464.
    13.    Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intern Med 1997 May 26;157 (10):1103–1108.
    14.    Philbin EF, Andreaou C, Rocco TA et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77 (10):832–838.
    15.    Luzier AB, Forrest A, Adelman M et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol. 1998;82 (4):465–469.
    16.    Luzier AB, Navsarikar A, Wilson MF et al. Patterns of prescribing ACE inhibitors after myocardial infarction. Pharmacotherapy 1999;19 (5):655–660.
    17.    Carter BL, Elliott WJ. The Role of Pharmacists in the Detection, Management, and Control of Hypertension: A National Call To Action. Pharmacotherapy. 2000;20 (2):119–122.
    18.    Limon L. Managing Risk vs Benefit in the Use of Medications: What Is the Pharmacist’s Role? Medscape Pharmacists, 2000.
    19.    Pedersen CA, Schneider PJ, Santell JP, Kelly EJ. ASHP National Survey of Pharmacy Practice in Acute Care Settings: Monitoring, Patient Education, and Wellness – 2000. Am J Health-Syst Pharm. 2000;57 (23):2171–2187.
    20.    Gilarevsky S, Baschinsky S., Boeva O. Health education for congestive heart failure. The Cochrane Library. – 2000 – N 4, protocol 9922.
    21.    Maggioni AP, Tavazzi L. Introducing new treatments in clinical practice: the Italian approach to beta blockers in heart failure. Heart. 1999;81 (5):453–454.
    22.    Working Group: Heart Failure. Italian network on outpatients with heart failure (IN-CHF). ANMCO – Italian Association of Hospital Cardiologists. Research activities year 2000.
    23.    Senni M, Gavazzi A. How patients with heart failure are managed in Italy. Eur J Heart Failure. 2001;3 (2):257–260.

To access this material please log in or register

Register Authorize
Ru En